PROMORE PHARMA
leading-edge medical innovation

Interim report, Jan-Dec 2021

- **All permissions received to start PHSU05**
- **Patent granted in the US for ropocamptide for the treatment of chronic wounds**
- **First patient was enrolled in PHSU05 in February 2022**



Promore Pharma AB (publ)

Interim report January - December 2021

October to December

- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -5.7 (-6.9), corresponding to earnings per share of SEK -0.09 (-0.21)
- Cash flow after financing activities amounted to MSEK -6.8 (-7.1)
- Cash amounted to MSEK 45.3 (24.2).

January to December

- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -26.8 (-29.4), corresponding to earnings per share of SEK -0.56 (-0.81)
- Cash flow after financing activities amounted to MSEK +21.1 (-36.3)

Significant events during January – December

- In January, the company entered into an agreement with Erik Penser Bank AB regarding services as Certified Adviser.
- In March, Promore Pharma decided on an adjustment of the company's strategy towards scar prevention in connection with surgery.
- In March, warrants corresponding to a dilution of 3.0% of the number of outstanding shares were deregistered.
- In April, an important milestone was achieved when the company signed an agreement with the Italian company Fidia.
- In May, a fully guaranteed new share issue of approximately MSEK 48 was announced.
- In May, the company received a granted patent in the US for prevention of skin scarring.
- In May, Hans-Peter Ostler was elected new member of the board.
- In June, the company announced that the new issue had been concluded, yielding a net MSEK 45.
- In September, Promore Pharma received delivery of hyaluronic acid from Italian manufacturer Fidia.
- In October, Promore Pharma announced that a scientific article had been published on the clinical study results of ropocamptide for venous leg ulcers.
- In November, Promore Pharma received permits to start a Phase II clinical trial regarding scar prevention.
- In December, the company received a granted patent for ropocamptide (LL-37) for the treatment of chronic wounds on the US market.

Events after the reporting period

- In January 2022, warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered.
- In February 2022, the first trial person was enrolled in PHSU05.

”In November, the year 2021 efforts in the ensereptide project culminated with an approval from the Swedish Medical Products Agency and the ethics authority to start PHSU05, our Phase II study for the prevention of skin scarring.”

Jonas Ekblom, President and CEO of Promore Pharma

Financial overview for the Company

Amounts in MSEK	Oct-Dec 2021	Oct-Dec 2020	Jan-Dec 2021	Jan-Dec 2020
Net sales	0.0	-	0.0	0.0
Operating loss	-5.7	-6.9	-26.7	-29.1
Profit/Loss for the period	-5.7	-7.8	-26.8	-29.4
Earnings per share, SEK	-0.09	-0.21	-0.56	-0.81
Cash flow after financing activities	-6.8	-7.1	21.1	-36.3
Cash and cash equivalents at the end of the period	45.3	24.2	45.3	24.2

Promore Pharma in brief:

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive healing of wounds. The company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

Statement of the CEO

The financial year 2021 was an important year for us at Promore Pharma. We made the strategic decision to orient our project regarding ensereptide towards prevention of skin scarring. As a result, we decided to carry out a rights issue of SEK 45 million net. On the one hand, the ownership in the company was broadened, and on the other hand, we received the financial resources required to be able to begin planning and later implement our Phase II study regarding ensereptide (PHSU05).

During the year, we negotiated agreements with reputable service providers for the manufacture of investigational product for the PHSU05 study, and during the autumn we were able to submit a clinical trial application for PHSU05, which was approved by the Medical Products Agency in Sweden during the fourth quarter. In 2021, we thus implemented the first part of the plan we laid out in connection with the new share issue.

In February 2022, slightly ahead of plan, the first subject was recruited to PHSU05. This gives us good hope of also being able to deliver the results from the study according to plan, i.e., during the winter of 2022/2023.

Our product candidate ensereptide is now being developed to inhibit various forms of scarring on the skin. As mentioned above, we adjusted the focus of this project in the spring of 2021. In 2021, we have in worked with preparations for a clinical Phase II trial (PHSU05) in this project. Among other things, we have entered into a manufacturing agreement with the Italian company Fidia for the production of the hyaluronic acid as well as certain manufacturing services. A batch was released according to GMP in late summer for use in the clinical study. The manufacture of the investigational product was completed during the autumn according to plan. In November, important sub-goals were reached in the ensereptide project with an approval from the Swedish Medical Products Agency and the Swedish Ethics Authority to start PHSU05.

We have also made significant progress in the ropocamptide project. We are now working on a technical development of an improved administration form for ropocamptide, where the main purpose is to develop a product that is easier to use. Regardless of whether the company conducts future clinical studies on its own or together with strategic partners, the development of a more user-friendly product is important both in a clinical study environment and when the product reaches the market. This work follows our business plan without deviations.

We are very grateful for the response we received in connection with the capital raise in June 2021. Both existing and several new resourceful shareholders have shown confidence in both the company and the reprioritization of the ensereptide project aimed at the scarring market. The capital injection enables several value-generating steps in Promore Pharma. The perseverance of our main owners, the company's employees, together with our strategic network, creates a robust company, which means that we have the strength to take on the challenges, temporary or permanent, that our industry is known for. The clearest example in 2020 and 2021 has, of course, been the societal restrictions caused by the COVID-19 pandemic. In Promore Pharma, we have over the past two years managed to advance the positions in our business with a remarkably small impact by the external situation.

In 2022, our most important operational goals are to continue and complete the plan we started in the summer of 2021, namely, to carry out our clinical trial of ensereptide for skin scarring and continue the work of creating a more user-friendly form of the product ropocamptide.

Finally, I would like to express my great gratitude to everyone who has provided support and hard work that made 2021 a fantastic year for Promore Pharma. Not least, I am grateful for the support that our shareholders have shown. It is gratifying to have been able to meet the expectations placed on the company. It is a privilege for me to have been involved in Promore Pharma's development in recent years, and I feel great enthusiasm to continue to lead the company forward.

Solna, February 16, 2022

Jonas Ekblom
President & CEO

Overview of activities

Promore Pharma is a biopharmaceutical company that develops peptide-based product candidates aimed at the bioactive wound care market. Ensereptide (PXL01) is aimed at prevention of post-surgical adhesions and scars and is being prepared for clinical Phase III studies on patients undergoing tendon repair surgery of the hand. Ropocamptide (LL-37) has recently passed clinical Phase IIb trial on patients with venous leg ulcers.

Promore Pharma's product candidates are based on innate peptides, which are a part of the human defense and healing system and have a strong safety profile since they are quickly degraded in the blood stream and are therefore unlikely to contribute to severe systemic adverse events. This is supported by the results from prior clinical studies, where both ensereptide and ropocamptide showed strong tolerability and safety as well as efficacy. The product candidates are protected by several international patent families offering protection until 2030 and longer. The patents provide protection in several dimensions, such as therapeutic use, formulation, and dosage ranges.

Promore Pharma's product candidates represent first-in-category therapeutics for several patient groups, segments where patients experience pain, reduced mobility, and lowered quality-of-life. When Promore Pharma's product candidates in clinical development receive market authorization and are established as treatment for chronic wounds and for preventing adhesions and scars, it would mean shorter treatment times for patients and lower costs for society.

Promore Pharma is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical aspects of the strategic planning process, including product development, regulatory affairs, design, and execution of clinical trials. Promore Pharma's overall strategy is to take the product candidates through clinical development to market authorization or to a point when a license agreement, alternatively a commercial deal with a larger pharmaceutical company with global presence, can be realized. Such transactions may include out-partnering/licensing, strategic partnerships, joint ventures, or asset sales.

About ensereptide (PXL01)

Ensereptide is derived from a human anti-bacterial protein (lactoferrin), which is part of the innate immune system. This protein and its peptide fragments have several modes of action, including immunomodulation and enhancement of fibrinolytic activity. It is well established that inflammation and fibrin formation after surgery or trauma are two pivotal mechanisms that strongly contribute to scar formation.

Ensereptide is aimed at local administration, and the development of the product is focused on preventing different kinds of scarring after surgery. In a Phase II clinical study that has been completed by the company in several countries of the European Union (EU), it has been demonstrated that ensereptide is efficacious and safe. Promore Pharma is preparing a clinical Phase II trial in the EU to explore the efficacy of the product for prevention of skin scarring. The study is planned to be initiated in the beginning of 2022.

Every year, more than 300 million surgical procedures are performed worldwide, and a proportion of these procedures result in disfiguring skin scars, for example after plastic and trauma surgery. Today, there are no drug products for prevention skin scarring after surgery. The addressable market is estimated to exceed SEK 100 billion. In other types of surgical procedures, there is a risk for occurrence of internal scars, which can cause adhesions (unfavorable attachments of tissues). This is a major medical problem, for example after surgical repair of injured tendons in the hand.

About ropocamptide (LL-37)

Ropocamptide is based on a human antimicrobial peptide, which stimulates several processes in wound healing. In a clinical Phase IIa study conducted by the company in patients with venous leg ulcers (VLUs), ropocamptide showed, in the most effective dose, an increase in the healing rate of relative wound area reduction of close to 70% after one month's treatment, suggesting a significantly higher efficacy than what has been reported for any other treatment in chronic wounds. No serious adverse events that were deemed to be caused by the investigational product occurred in the trial. The product candidate can be easily combined with the standard wound care treatments and given by a nurse or the patient.

The development of ropocamptide is initially focused on venous leg ulcers and the company has recently concluded a clinical Phase IIb study (HEAL LL-37) on patients with VLUs in Europe. VLUs constitute the largest category of all chronic or hard-to-heal ulcers and represent significant challenges to patients and healthcare systems since they are frequent, costly to manage, recurring, and may persist for months or years.

The development of ropocamptide focuses initially on VLUs but the company sees good potential in also developing ropocamptide for diabetic foot ulcers.

Significant events during January – December 2021

Change of Certified Adviser ("CA") to Erik Penser Bank AB

In January, Promore Pharma AB entered into an agreement with Erik Penser Bank AB regarding the CA service. Erik Penser Bank assumed the role on 25 January 2021. Until then, Redeye AB acted as CA for the company.

Update of strategy and focus on scar prevention

In March, Promore Pharma's board decided to adjust the company's strategy. The development of the drug candidate ensereptide (PXL01) will focus on scar prevention in connection with surgery. The decision is based on a strong and improved patent situation in the USA and that a robust production process has been ensured. The changed strategic priorities mean that the capital requirement for the company is considerably reduced and at the same time ensereptide can address a significantly larger market than before.

Deregistration of warrants

In March, Promore Pharma announced that the company had 72,755 warrants deregistered, corresponding to a dilution of 3.0% in programs 3-7 issued to Technomark Group USA LLC and Kentron Biotechnology Pvt Ltd. The warrants were issued in 2016 as part of the remuneration for planned CRO services in the clinical trial PHSU03. There are 54,599 warrants remaining related to programs 1, 2 and 8, respectively.

Agreement signed on production of hyaluronic acid with Italian manufacturer Fidia

In April, Promore Pharma AB and Fidia Farmaceutici S.p.A. ("Fidia") signed an agreement for the production of hyaluronic acid, which is one of the components of Promore Pharma's investigational drug, ensereptide. Fidia is a world-leading manufacturer of pharmaceutical-grade hyaluronic acid, and the agreement will make it possible for Promore Pharma to procure raw material of optimal quality at the required future scale. Ensereptide is being developed as a treatment to prevent skin scarring and post-surgical adhesions.

Intention to carry out a fully secured rights issue in order to implement the new strategy

In May, the Board of Promore Pharma AB resolved to carry out a rights issue with preferential rights for the Company's existing shareholders of SEK 48.6 million before transaction costs for the purpose of implementing the new strategy that was communicated on 31 March 2021. The subscription price amounts to SEK 2.00 per new share. Through the Rights Issue, the planned Phase II study for ensereptide (PXL01) and the technical development of the administration form for ropocamptide (LL-37) will be fully financed.

Patent granted in the US regarding skin scarring

In May, Promore Pharma announced that the company had received a granted patent in the US for the use of the candidate drug ensereptide (PXL01) to prevent the formation of scarring on the skin.

Outcome in the new issue

In June it was announced that the company's rights issue with preferential rights for the shareholders ended on 17 June 2021. The subscription breakdown showed that 89.2 percent was subscribed with and without the exercise of subscription rights. Consequently, underwriting parties will be allocated 10.8 percent of the Rights Issue thus resulting in a fully subscribed Rights Issue and that Promore Pharma obtains SEK 48.6 million before issue costs.

Delivery of hyaluronic acid from Italian manufacturer Fidia

In September the company announced that hyaluronic acid, a product component of ensereptide, had been manufactured, released according to Good Manufacturing Practice, and delivered to Promore Pharma.

A scientific article has been published on clinical study results of ropocamptide for venous leg ulcers

In October it was announced that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers had been published in the journal "Wound Repair and Regeneration".

Permission to start a Phase II clinical trial regarding scar prevention

In November it was announced that the company had received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical Phase II trial of ensereptide for skin scarring prevention.

Events after the reporting period

Deregistration of warrants

In January 2022, warrants related to program 1 & 2, corresponding to a dilution of 0.2% of the number of outstanding shares, were deregistered.

First patient in PHSU05 enrolled

I the middle of February, the first patient of approx. 24 was enrolled in PHSU05, the company's Phase II study for the prevention of scars in conjunction with surgery.

Financial information

Net sales and result for the fourth quarter 2021

The company has no revenues from products sales, therefore the company's revenue amounted to MSEK 0.0 (0.0) in the period.

The company's costs for raw materials and consumables are mainly related to development costs, such as costs for clinical trials, patents, products for the clinical trials and consultants working with the development of the company's candidate drugs. In the quarter, these costs amounted to MSEK 2.5 (4.3). The decrease is mainly explained by the fact that the company still had costs for the HEAL LL-37 study last year, while we haven't had the same study activity this year.

Other external costs amounted to MSEK 2.4 (1.5), where the increase is mainly due to higher consultancy costs.

Personnel expenses costs were MSEK 1.2, which is MSEK 0.2 higher compared to the same period last year.

The operating loss for the period amounted to MSEK -5.7, compared to MSEK -6.9 in 2020. Net loss for the period amounted to MSEK -5.7 (-7.8), corresponding to earnings per share of SEK -0.09 (-0.21).

Net sales and result for the fiscal year 2021

The company has no revenues from products sales, however, costs of MSEK 0.4 (0.0) have been invoiced onward in the period.

The company's costs for raw materials and consumables are mainly related to development costs, such as costs for clinical trials, patents, products for the clinical trials and consultants working with the development of the company's candidate drugs. In the period, costs amounted to MSEK 15.3 (18.2), of which MSEK 2.2 is related to the closure of HEAL LL-37 during the first quarter. The decrease is mainly explained by the fact that the company still had costs for the HEAL LL-37 study last year, while we haven't had the same study activity this year.

Other external costs amounted to MSEK 7.1 (6.0), where the increase is mainly due to new reporting principles regarding remuneration to the board and higher advertising costs.

Personnel expenses costs were MSEK 4.7, which is MSEK 0.4 higher compared to the same period previous year.

The operating loss for the period amounted to MSEK -26.7 compared to MSEK -29.1 last year. Net loss for the period amounted to MSEK -26.8 (-29.4), corresponding to earnings per share of SEK -0.56 (-0.81).

Cashflow, liquidity and financing

The cash flow from operating activities during FY 2021 amounted to MSEK -26.9 (-28.6). The decrease is primarily related to lower clinical trial related costs, and a large negative change in working capital in the first quarter last year.

The cash flow from investment activities amounted to MSEK +1.0 (+1.5), which is related to the sale of the final shares in Herantis Pharma Oyj.

The cash flow from financing activities was MSEK +44.7 (0.0) during the period, which relates to the net proceeds from the new issue.

The company's cash and cash equivalents amounted to MSEK 45.3 by 31 December 2021, compared to MSEK 52.1 by 30 September 2021, MSEK 13.1 by 30 June 2021, MSEK 18.6 by 31 March 2021 and MSEK 24.2 by 31 December 2020. The net proceeds of MSEK 44.7 from the new issue were transferred to the company in July 2021.

Auxiliary information

Risks

Regarding the outbreak of coronavirus and COVID-19, Promore Pharma is following the development closely and taking relevant measures to minimize the impact on the company's business. Promore Pharma is following the guidelines from "Folkhälsomyndigheten" (The Public Health Agency of Sweden) and other authorities. Until now, COVID-19 has only had minor effects on Promore Pharma's operations, but the company may have to revise the time plans if the pandemic becomes long-lasting.

Further information about risks and uncertainties can be obtained from the company's website, www.promorepharma.com.

Number of shares

Promore Pharma's share is listed on Nasdaq First North (now Nasdaq First North Growth Market) in Stockholm since 6 July 2017 with the ticker PROMO and ISIN code SE0009947740.

The 24.285.574 shares from the new issue were officially recorded in the beginning of July, why the average number of shares in Q4 increased from 36,428,362 to 60,713,936, while the number of shares at the end of the period amounted to 60,713,936.

Number of shares	Oct-Dec		Jan-Dec	
	2021	2020	2021	2020
Average number of shares	60,713,936	36,428,362	47,694,170	36,428,362
Number of shares by the end of the period	60,713,936	36,428,362	60,713,936	36,428,362

After the new issue, the main owners Corespring New Technology AB* and PharmaResearch Co. Ltd together own just below 50% of the shares in the company.

Ownership Promore Pharma per 2021-12-31	number	share
Corespring New Technology AB*	22,710,730	37.4%
PharmaResearch Co. Ltd.	7,468,132	12.3%
Nordnet Pensionsförsäkring AB	4,319,783	7.1%
Daniel Johnsson	3,740,036	6.2%
Exceca Allocation/Alsteron	3,332,584	5.5%
Arne Andersson	3,283,546	5.4%
Avanza Pension Försäkringsaktiebolag	1,999,996	3.3%
Other	13,859,129	22.8%
TOTAL	**60,713,936**	**100.0%**

*formerly Midroc New Technology AB

Warrants – external partners

The company announced in March 2021 that, as a consequence of the changed priority for ensereptide, a total of 72,755 warrants (1,091,325 after split) in programs 3-7 issued in 2016 with a dilution effect of approximately 3.0% have been deregistered. After this, 54,599 warrants (818,985 after split) remain related to programs 1, 2 and 8, with a dilution effect of approximately 2.2%. After the period, another 9 144 warrants (137,160 after split), corresponding to 0.2% of the shares, related to program 1 & 2 been deregistered.

Warrants – LTI 2020

It was resolved at the Annual General Meeting in 2020 to adopt a performance-based stock savings program (LTI 2020) for certain employees and contractors in Promore Pharma. A maximum of 1,400,000 Performance Share Rights may be allotted under LTI 2020, corresponding to approximately 3.7 percent of the shares in the company.

In accordance with the Board's proposal, it was resolved that a directed issue of 1,800,000 warrants with the right to subscribe for new shares in the company be used to implement LTI 2020. For those who are offered to join LTI 2020 and previously participated in the company's old bonus program, the old bonus agreements will be terminated without any awards.

Holding of shares in Herantis Pharma Oyj

The company has held shares in the Finnish biotech company Herantis Pharma Oyj. This is a consequence of a passive historic holding in the Finnish company Biocis Oy since the formation of Pergamum AB in 2010. Biocis has since then undergone a number of corporate mergers and ownership restructurings which has resulted in a holding of shares in Herantis Pharma Oyj, a company that executed an IPO in 2015. The last part of the shares were divested in Q1 2021.

Personnel

Promore Pharma has a small and cost-effective organization that is primarily focused on business development, project coordination as well as management of intellectual property and core development documentation. All personnel except the CEO operate on a consultancy basis. Per 31 December 2021, the company consequently had one employee.

Transactions with related parties

The company has not had any transactions with related parties during the period.

Accounting principles

The report has been drawn up in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Accounting Standards Board's (BFNAR) General Recommendation 2012:1: Annual Report and Consolidated Accounts ("K3").

Financial calendar 2022

Q1 report	17 May
AGM	17 May
Q2 report	30 August
Q3 report	29 November

Review by auditor

This report has not been reviewed by the Company's auditor.

The Board's declaration

The Board of Directors and the CEO assure that this report provides a fair overview of the company's operations, position, and results.

Solna 16 February 2022

Göran Pettersson

Ordförande

Marianne Dicander Alexandersson

Göran Linder

Kerstin Valinder Strinnholm

Satyendra Kumar

Hans-Peter Ostler

Consolidated income statement

Amounts in SEK	Oct-Dec 2021	Oct-Dec 2020	Jan-Dec 2021	Jan-Dec 2020
Operating income				
Net sales	18	-	18	3
Other operating income	423	-5	417	14
Operating expenses				
Commodities and supplies	-2,529	-4,304	-15,312	-18,205
Other external expenses	-2,359	-1,495	-7,127	-6,038
Personnel costs	-1,249	-1,050	-4,690	-4,274
Depreciation and impairments on fixed assets	-	-	-	-609
Other operating expenses	12	-0	-	-30
Operating loss (EBIT)	**-5,684**	**-6,854**	**-26,694**	**-29,138**
Financial items				
Net financial items	-10	-898	-78	-311
Profit/loss after financial items	**-5,694**	**-7,752**	**-26,772**	**-29,449**
Profit/loss before tax	**-5,694**	**-7,752**	**-26,772**	**-29,449**
Tax	-	-	-	-
Profit/Loss for the period	**-5,694**	**-7,752**	**-26,772**	**-29,449**

Consolidated balance sheet

Amounts in SEK	31 Dec 2021	2020
ASSETS		
FIXED ASSETS		
Intangible fixed assets	-	-
Financial fixed assets	1	1,068
Total fixed assets	**1**	**1,068**
CURRENT ASSETS		
Current receivables	328	239
Accounts receivable	-	-
Other receivables	1,555	661
Cash and cash equivalents	45,317	24,249
Total current assets	**47,200**	**25,150**
TOTAL ASSETS	**47,201**	**26,217**
EQUITY AND LIABILITIES		
EQUITY		
Share capital	2,429	1,457
Other equity including the result for the period	38,178	21,332
Total equity	**40,607**	**22,789**
LONG-TERM LIABILITIES		
Liabilities to credit institutions	714	714
Other liabilities	237	107
Total long-term liabilities	**951**	**821**
CURRENT LIABILITIES		
Accounts payable	4,002	1,023
Deferred taxes	146	146
Other current liabilities	1,495	1,439
Total current liabilities	**5,643**	**2,608**
TOTAL EQUITY AND LIABILITIES	**47,201**	**26,217**

Consolidated cash flow analysis

Amounts in SEKk	Oct-Dec 2021	Oct-Dec 2020	Jan-Dec 2021	Jan-Dec 2020
OPERATING ACTIVITIES				
Operating profit	-5,684	-6,854	-26,694	-29,138
Adjustments for items not included in cash flow	-160	-3	-190	592
Tax paid	-	-	-	-
Cash flow from operating activities before changes in working capital	**-5,844**	**-6,856**	**-26,884**	**-28,547**
Increase/decrease other current receivables	-1,005	700	-982	3,873
Increase/decrease other current liabilities	19	-1,418	3,035	-12,804
Cash flow from operating activities	**-6,830**	**-7,574**	**-24,831**	**-37,479**
INVESTING ACTIVITIES				
Sale of financial fixed assets	-	709	1,159	1,448
Cash flow from investing activities	**-**	**709**	**1,159**	**1,448**
FINANCING ACTIVITIES				
New share issue	-	-	44,740	-
Loans	-	-	-	-
Repaid loans	-	-235	-	-264
Cash flow from financing activities	**-**	**-235**	**44,740**	**-264**
Cash flow for the period	**-6,830**	**-7,100**	**21,068**	**-36,294**
Cash and cash equiv. at the beginning of the period	**52,146**	**31,348**	**24,249**	**60,543**
Exchange rate difference cash and cash equivalents	-	-	-	-
Cash and cash equiv. at the end of the period	**45,317**	**24,249**	**45,317**	**24,249**

Change in equity for the group

EQUITY

Amounts in SEKk	Share capital	Other paid-in capital	Other equity	Total equity
Amount at the beginning of the period (1 Jan 2021)	1,457	-	**21,332**	**22,789**
New share issue	972	-	43,768	44,740
Repurchased warrants	-	-	-150	-150
Profit for the period	-	-	-26,772	-26,772
Amount at the end of the period (31 Dec 2021)	**2,429**	**-**	**38,178**	**40,607**
Amount at the beginning of the period (1 Jan 2020)	1,457	-	**50,736**	**52,193**
New share issue	-	-	-	-
Profit for the period	-	-	-29,449	-29,449
Amount at the end of the period (31 Dec 2020)	**1,457**	**-**	**21,287**	**22,744**

Parent company income statement

Promore Pharma AB, parent company	Oct-Dec		Jan-Dec	
Amounts in SEKk	2021	2020	2021	2020
OPERATING INCOME				
Net sales	18	-	18	-
Other operating income	424	-1	412	17
OPERATING EXPENSES				
Commodities and supplies	-2,517	-4,137	-15,140	-17,892
Other external expenses	-2,274	-1,488	-7,022	-5,898
Personnel costs	-1,249	-1,050	-4,689	-4,274
Depreciation and amortization of tangible assets	-	-	-	-608
Total operating expenses	-7	-0	-16	-25
Operating profit/loss (EBIT)	**-5,604**	**-6,676**	**-26,437**	**-28,679**
FINANCIAL ITEMS				
Net financial items	-	235	-150	235
Profit/Loss after financial items	**-5,604**	**-6,442**	**-26,587**	**-28,445**
Extra-ordinary items	-	-	-	-
Pre-tax profit	**-5,604**	**-6,442**	**-26,587**	**-28,445**
Tax	-	-	-	-
Net profit/loss for the period	**-5,604**	**-6,442**	**-26,587**	**-28,445**

Parent company balance sheet

Promore Pharma AB, parent company	31 Dec	
Amounts in SEKk	2021	2020
Non-current assets		
Share in other long-term securities holdings	10,398	10,398
Total fixed assets	**10,398**	**10,398**
Current assets		
Accounts receivables	328	-
Receivables from group companies	4,805	4,805
Current tax assets	144	144
Other current receivables	713	594
Prepaid expenses and accrued revenue	521	150
Cash and bank balances	39,330	19,014
TOTAL CURRENT ASSETS	**45,839**	**24,706**
TOTAL ASSETS	**56,238**	**35,104**
Equity		
Restricted equity		
Share capital	2,429	1,457
Reserve fund	380	380
Total restricted equity	**2,809**	**1,837**
Unrestricted equity		
Share premium reserve	220,462	176,693
Loss brought forward	-146,301	-118,317
Profit/Loss for the period	-26,567	-27,834
Total unrestricted equity	**47,595**	**30,542**
Total equity	**50,404**	**32,380**
LONG-TERM LIABILITIES		
Other liabilities	237	107
TOTAL LONG-TERM LIABILITIES	**237**	**107**
CURRENT LIABILITIES		
Accounts payables	3,934	1,021
Liabilities to group companies	-	-
Current tax liabilities	347	244
Other current liabilities	-	-
Accrued expenses and deferred income	1,316	1,352
TOTAL CURRENT LIABILITIES	**5,597**	**2,618**
TOTAL EQUITY AND LIABILITIES	**56,238**	**35,104**

Parent company cash flow analysis

Promore Pharma AB, parent company	Oct-Dec		Jan-Dec	
Amounts in SEKk	2021	2020	2021	2020
Operating activities				
Operating loss	-5,604	-6,676	-26,437	-28,679
Adjustments for non-cashflow items	-149	471	-147	1,248
Tax paid	-	-	-	-
Cash flow from operating activities before changes in working capital	**-5,753**	**-6,206**	**-26,584**	**-27,432**
Change in accounts receivables	-819	702	-818	4,020
Change in accounts payable	-21	-1,398	2,980	-12,847
Cash flow from operating activities	**-6,593**	**-6,902**	**-24,422**	**-36,258**
INVESTMENT ACTIVITIES				
Divestiture of financial assets	-	-	-	-
Cash flow from investment activities	**-**	**-**	**-**	**-**
FINANCING ACTIVITIES				
New share issue	-	-	44,740	-
New loans	-	-	-	-
Repaid loans	-	-235	-	-264
Cash flow from financing activities	**-**	**-235**	**44,740**	**-264**
Cash flow for the period	**-6,593**	**-7,137**	**20,318**	**-36,522**
Cash and bank balances in the beginning of the period	**45,925**	**26,385**	**19,014**	**55,771**
Exchange rate difference cash and cash equivalents	-	-	-	-
Cash and bank balances at year end	**39,331**	**19,248**	**39,331**	**19,248**

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

Email: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 56 52 45

Email: erik.magnusson@promorepharma.com

Street address: Fogdevreten 2, 171 65 Solna, Sweden

Website: www.promorepharma.com

Corporate registration number: 556639-6809

Promore Pharma's Certified Adviser is Erik Penser Bank AB .

Phone: [+46] 8 463 83 00

Email: certifiedadviser@penser.se